Application of metabolic marker in preparation of product for auxiliary diagnosis of retinal vein occlusion or evaluation of treatment prognosis of ginseng-wolfberry omentum granules

By screening 14 characteristic metabolic biomarkers using metabolomics technology, the efficacy of Shenqi Reticulum Granules in treating RVO was identified, which solved the problem of unclear efficacy. This enabled auxiliary diagnosis and efficacy monitoring of RVO and promoted the standardization and precision development of traditional Chinese medicine compound prescriptions.

CN121917675APending Publication Date: 2026-04-24SHANGHAI JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANGHAI JIAOTONG UNIV
Filing Date
2026-01-22
Publication Date
2026-04-24

AI Technical Summary

Technical Problem

The pharmacodynamic material basis and overall mechanism of action of ginseng and wolfberry retinal granules in the treatment of retinal vein occlusion (RVO) in the existing technology are unclear, lack specific biomarkers, and make it difficult to establish a quality control system and assess prognosis.

Method used

Using non-targeted metabolomics technology, 14 characteristic metabolic biomarkers were systematically screened and identified by constructing an RVO disease model. These biomarkers were used to assist in the diagnosis and evaluation of the therapeutic effect of Shenqi Reticulum Granules and to establish a quality evaluation method based on pharmacodynamic biomarkers.

Benefits of technology

The system reveals the multi-target mechanism of action of ginseng and wolfberry reticulum granules, provides a standardized and precise development path for traditional Chinese medicine compound prescriptions, enhances the clinical translational value of traditional Chinese medicine compound prescriptions, and realizes the auxiliary diagnosis and efficacy monitoring of RVO.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121917675A_ABST
    Figure CN121917675A_ABST
Patent Text Reader

Abstract

The invention belongs to the crossing field of traditional Chinese medicine modernization and biotechnology, and particularly relates to application of a metabolic marker in preparation of a product for auxiliary diagnosis of retinal vein occlusion (RVO) or evaluation of prognosis of treatment of RVO by ginseng-wolfberry omentum granules. The metabolic marker is selected from at least one of the following metabolites: leukotriene B4, (R)-2-feruloyl-1-(4-hydroxyphenyl)-1, 2-ethylene glycol, hyoscyamine base A6, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxy-5, 6, 7, 8, 9, 10, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxyl-5, 6, 7, 8, 10-tetrahydroxyl-5, 7, 8, 10 The invention relates to an anti-inflammatory agent which is prepared from 5, 5 '-diisopropyl-2, 2'-dimethyl biphenyl (3, 3 ', 4, 4', 1-ethyl piperidine, flavin mononucleotide, crystal orchid glycoside, 2-O-caffeoyl arbutin, dimethyl ellagic acid glucuronide, 4 '-hydroxy-3, 4, 5-resveratrol trimethyl ether, 3'-methoxy petamicin, phenylalanyl-leucyl-isoleucyl-tyrosine and dihydroferulic acid-4-sulfate.
Need to check novelty before this filing date? Find Prior Art